Compare Amgen, Inc. (AMGN) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Dolby Laboratories, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Dolby Laboratories, Inc. trades at $49.85 (market cap $4.71B). The key difference: Amgen, Inc. is far larger — about 41.6× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| AMGN | DLB | |
|---|---|---|
Market Cap | $196.12B | $4.71B |
Sector | Health | Industrials |
52-Week High | $388.16 | $76.79 |
52-Week Low | $271.18 | $49.31 |
Enterprise Value | $241.41B | $4.17B |
Dividend Yield | 2.77% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DLB trades at $49.8, down 0.64% on the day, with a bearish technical outlook but strong fundamentals. Recent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected, highlight operational strength. The company maintains high gross margins of 87.44% and positive cash flow, supported by licensing growth and expanding Dolby Atmos adoption.
The stock presents a value opportunity with a P/E of 19.76 below historical averages, and a consensus price target of $87.50 implies significant upside. Risks include cyclical end-market exposure and potential dilution from pipeline developments. Analyst sentiment is moderately bullish, but technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
